<DOC>
	<DOCNO>NCT02852837</DOCNO>
	<brief_summary>The purpose study evaluate tolerability , safety pharmacokinetic ( PK ) profile daratumumab Chinese participant relapse refractory multiple myeloma ( MM ) fail least 2 prior line systemic therapy .</brief_summary>
	<brief_title>Dose Escalation Study JNJ-54767414 ( Daratumumab ) Chinese Participants With Relapsed Refractory Multiple Myeloma Who Failed Least 2 Prior Lines Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Documented multiple myeloma ( MM ) measurable disease accord protocoldefined criterion Relapsed refractory multiple myeloma receive least 2 prior line therapy Eastern Cooperative Oncology Group performance status score 0 , 1 , 2 Adequate recovery prior therapy Received daratumumab antiCD38 therapy previously Previously receive allogenic stem cell transplant receive autologous stem cell transplantation within 12 week Exhibiting clinical sign meningeal involvement multiple myeloma Known chronic obstructive pulmonary disease , know moderate severe persistent asthma within past 2 year , uncontrolled asthma classification Known clinically significant cardiac disease Seropositive human immunodeficiency virus , hepatitis B surface antigen positivity , positive antihepatitis C virus antibody Has plasma cell leukemia , Waldenstrom 's macroglobulinemia , POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) , amyloidosis Abnormal laboratory value accord protocoldefined parameter screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>